Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Tabalumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Tabalumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Tabalumab. |
| Estrone | Estrone may increase the thrombogenic activities of Tabalumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Tabalumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Tabalumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Tabalumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Tabalumab. |
| Estriol | Estriol may increase the thrombogenic activities of Tabalumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Tabalumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Tabalumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Tabalumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Tabalumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tabalumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tabalumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Tabalumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Tabalumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Tabalumab. |
| Equol | Equol may increase the thrombogenic activities of Tabalumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Tabalumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Tabalumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Tabalumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Tabalumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Tabalumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Tabalumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Tabalumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Tabalumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Tabalumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Tabalumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Tabalumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Tabalumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tabalumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Tabalumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Tabalumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Tabalumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tabalumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tabalumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Tabalumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tabalumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Tabalumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Tabalumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Tabalumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tabalumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tabalumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Tabalumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tabalumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tabalumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Tabalumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tabalumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Tabalumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Tabalumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Tabalumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tabalumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tabalumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Tabalumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Tabalumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tabalumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Tabalumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tabalumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tabalumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tabalumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Tabalumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Tabalumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Tabalumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tabalumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tabalumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Tabalumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tabalumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Tabalumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Tabalumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tabalumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Tabalumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tabalumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Tabalumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tabalumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Tabalumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tabalumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Tabalumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Tabalumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Tabalumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tabalumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tabalumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tabalumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tabalumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tabalumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Tabalumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Tabalumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tabalumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Tabalumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Tabalumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Tabalumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Tabalumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tabalumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Tabalumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tabalumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Tabalumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tabalumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tabalumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Tabalumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tabalumab. |